Incannex Healthcare Inc
IXHL0.152USD
-0.458-75.10%
Fechamento 04/29, 16:00（ET）Cotações atrasadas em 15 min
2.70MValor de mercado
PerdaP/L TTM
Mais detalhes de Incannex Healthcare Inc Empresa
Incannex Healthcare Inc. is a clinical-stage pharmaceutical development company. The Company is developing medicinal cannabinoid pharmaceutical products and psychedelic medicine therapies for the treatment of obstructive sleep apnea (OSA), traumatic brain injury (TBI) and concussion, lung inflammation (ARDS, COPD, asthma, bronchitis), rheumatoid arthritis, inflammatory bowel disease, anxiety disorders, addiction disorders, and pain, among other indications. The Company’s diversified portfolio includes 28 distinct research and development (R&D) programs, and six clinical trials underway. Its clinical projects include IHL-42X Obstructive Sleep Apnea, IHL-675A Inflammatory Lung Disease, IHL-675A Rheumatoid Arthritis, IHL-675A Inflammatory Bowel Disease, IHL-216A Concussion and TBI, PSI-GAD Psilocybin for anxiety, MedChew GB Post-herpatic Neuralgia and MedChew -1401 Pain and Spasticity in Multiple Sclerosis.
Informações da empresa
Código da empresaIXHL
Nome da EmpresaIncannex Healthcare Inc
Data de listagemMar 18, 2022
Fundado em2023
CEOMr. Joel Latham
Número de funcionários9
Tipo de títulosOrdinary Share
Fim do ano fiscalMar 18
Endereço18 East 50th Street
CidadeNEW YORK
Bolsa de valoresNASDAQ Global Market Consolidated
PaísUnited States of America
Código postal10022
Telefone
Site
Código da empresaIXHL
Data de listagemMar 18, 2022
Fundado em2023
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Joel Latham
Mr. Joel Latham
President, Chief Executive Officer, Executive Director
President, Chief Executive Officer, Executive Director
1.58M
--
Dr. George Anastassov
Dr. George Anastassov
Non-Executive Independent Director
Non-Executive Independent Director
769.72K
--
Mr. Peter Widdows
Mr. Peter Widdows
Non-Executive Independent Director
Non-Executive Independent Director
270.85K
--
Mr. Joseph Swan
Mr. Joseph Swan
Chief Financial Officer, Controller, Treasurer, Company Secretary
Chief Financial Officer, Controller, Treasurer, Company Secretary
169.20K
+146.20%
Mr. Troy Valentine
Mr. Troy Valentine
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
--
--
Mr. Lekhram Changoer
Mr. Lekhram Changoer
Chief Technology Officer
Chief Technology Officer
--
--
Dr. Luigi M. (Lou) Barbato, M.D.
Dr. Luigi M. (Lou) Barbato, M.D.
Chief Medical Officer
Chief Medical Officer
--
--
Mr. Robert B. Clark
Mr. Robert B. Clark
Non-Executive Independent Director
Non-Executive Independent Director
--
--
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Joel Latham
Mr. Joel Latham
President, Chief Executive Officer, Executive Director
President, Chief Executive Officer, Executive Director
1.58M
--
Dr. George Anastassov
Dr. George Anastassov
Non-Executive Independent Director
Non-Executive Independent Director
769.72K
--
Mr. Peter Widdows
Mr. Peter Widdows
Non-Executive Independent Director
Non-Executive Independent Director
270.85K
--
Mr. Joseph Swan
Mr. Joseph Swan
Chief Financial Officer, Controller, Treasurer, Company Secretary
Chief Financial Officer, Controller, Treasurer, Company Secretary
169.20K
+146.20%
Mr. Troy Valentine
Mr. Troy Valentine
Non-Executive Chairman of the Board
Non-Executive Chairman of the Board
--
--
Mr. Lekhram Changoer
Mr. Lekhram Changoer
Chief Technology Officer
Chief Technology Officer
--
--
Detalhamento da receita
FY2025Q1
FY2024
FY2024Q4
FY2022
Sem dados
Por RegiãoUSD
Nome
Receita
Proporção
Australia
74.00K
0.00%
Por Empresa
Por Região
Sem dados
Acionista
Tempo de atualização: ter, 8 de abr
Tempo de atualização: ter, 8 de abr
Estatísticas dos acionistas
Tipo
Estatísticas dos acionistas
Acionista
Proporção
L1 Capital Global Opportunities Master Fund Ltd.
7.00%
S.H.N. Financial Investments Ltd
7.00%
Latham (Joel)
5.73%
Valentine (Troy Robert)
3.76%
Anastassov (George)
2.79%
Other
73.71%
Estatísticas dos acionistas
Acionista
Proporção
L1 Capital Global Opportunities Master Fund Ltd.
7.00%
S.H.N. Financial Investments Ltd
7.00%
Latham (Joel)
5.73%
Valentine (Troy Robert)
3.76%
Anastassov (George)
2.79%
Other
73.71%
Tipo
Acionista
Proporção
Individual Investor
16.57%
Corporation
14.01%
Investment Advisor
0.82%
Research Firm
0.37%
Investment Advisor/Hedge Fund
0.07%
Other
68.18%
Participação acionária institucional
Tempo de atualização: ter, 4 de mar
Tempo de atualização: ter, 4 de mar
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q1
36
9.08M
33.58%
+3.85M
2024Q4
34
5.22M
29.25%
-10.87K
2024Q3
35
5.23M
32.43%
+928.92K
2024Q2
32
5.32M
33.29%
+935.04K
2024Q1
33
4.38M
27.39%
+2.50M
2023Q4
26
4.32M
27.01%
+2.81M
2023Q3
13
32.37K
0.05%
-34.33K
2023Q2
11
12.21K
0.02%
-63.09K
2023Q1
10
20.53K
0.03%
-60.83K
2022Q4
10
50.18K
0.08%
-3.79K
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
L1 Capital Global Opportunities Master Fund Ltd.
1.93M
7%
+1.93M
--
Mar 10, 2025
S.H.N. Financial Investments Ltd
1.93M
7%
+1.93M
--
Mar 10, 2025
Latham (Joel)
1.58M
5.73%
--
--
Oct 21, 2024
Valentine (Troy Robert)
1.04M
3.76%
--
--
Oct 21, 2024
Anastassov (George)
769.72K
2.79%
--
--
Oct 21, 2024
Changoer Lekhram
639.55K
2.32%
--
--
Oct 21, 2024
Widdows (Peter)
270.85K
0.98%
--
--
Oct 21, 2024
Swan (Joseph)
169.20K
0.61%
+100.48K
+146.20%
Oct 23, 2024
AdvisorShares Investments, LLC
165.50K
0.6%
+38.51K
+30.32%
Dec 31, 2024
Clark (Robert)
100.00K
0.36%
--
--
Oct 21, 2024
Ver Mais
ETFs Relacionados
Tempo de atualização: dom, 6 de abr
Tempo de atualização: dom, 6 de abr
Nome
Proporção
AdvisorShares Psychedelics ETF
4.37%
Amplify Alternative Harvest ETF
0%
AdvisorShares Psychedelics ETF
Proporção4.37%
Amplify Alternative Harvest ETF
Proporção0%
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados